Home

vario Miglioramento Riconoscimento cd40 antibody clinical trial Anguilla Economico clic

Dendritic cell targeting with Fc-enhanced CD40 antibody agonists induces durable antitumor immunity in humanized mouse models of bladder cancer | Science Translational Medicine
Dendritic cell targeting with Fc-enhanced CD40 antibody agonists induces durable antitumor immunity in humanized mouse models of bladder cancer | Science Translational Medicine

Safety and Immune Effects of Blocking CD40 Ligand in Multiple Sclerosis | Neurology Neuroimmunology & Neuroinflammation
Safety and Immune Effects of Blocking CD40 Ligand in Multiple Sclerosis | Neurology Neuroimmunology & Neuroinflammation

Agonistic CD40 therapy induces tertiary lymphoid structures but impairs responses to checkpoint blockade in glioma | Nature Communications
Agonistic CD40 therapy induces tertiary lymphoid structures but impairs responses to checkpoint blockade in glioma | Nature Communications

Novel combination immunotherapy for pancreatic cancer: potent anti‐tumor effects with CD40 agonist and interleukin‐15 treatment - Van Audenaerde - 2020 - Clinical & Translational Immunology - Wiley Online Library
Novel combination immunotherapy for pancreatic cancer: potent anti‐tumor effects with CD40 agonist and interleukin‐15 treatment - Van Audenaerde - 2020 - Clinical & Translational Immunology - Wiley Online Library

Next-IO™ Anti-CD40 Therapeutic Monoclonal Antibody Program - Creative Biolabs
Next-IO™ Anti-CD40 Therapeutic Monoclonal Antibody Program - Creative Biolabs

CD40
CD40

PDF] Agonistic CD40 Antibodies and Cancer Therapy | Semantic Scholar
PDF] Agonistic CD40 Antibodies and Cancer Therapy | Semantic Scholar

Anti-CD40 antibody KPL-404 inhibits T cell-mediated activation of B cells from healthy donors and autoimmune patients | Arthritis Research & Therapy | Full Text
Anti-CD40 antibody KPL-404 inhibits T cell-mediated activation of B cells from healthy donors and autoimmune patients | Arthritis Research & Therapy | Full Text

Side effects of CD40 agonistic antibodies versus fusion molecules. | Download Scientific Diagram
Side effects of CD40 agonistic antibodies versus fusion molecules. | Download Scientific Diagram

InVivoMAb anti-mouse CD40 | Bio X Cell
InVivoMAb anti-mouse CD40 | Bio X Cell

CD40: Targeting Co-Stimulatory Pathways for Cancer Immunotherapy
CD40: Targeting Co-Stimulatory Pathways for Cancer Immunotherapy

Therapeutic Activity of Agonistic, Human Anti-CD40 Monoclonal Antibodies Requires Selective FcγR Engagement - ScienceDirect
Therapeutic Activity of Agonistic, Human Anti-CD40 Monoclonal Antibodies Requires Selective FcγR Engagement - ScienceDirect

Frontiers | Next Generation CD40 Agonistic Antibodies for Cancer Immunotherapy
Frontiers | Next Generation CD40 Agonistic Antibodies for Cancer Immunotherapy

Frontiers | CD40L and Its Receptors in Atherothrombosis—An Update
Frontiers | CD40L and Its Receptors in Atherothrombosis—An Update

IJMS | Free Full-Text | FcγRs and Their Relevance for the Activity of Anti-CD40 Antibodies
IJMS | Free Full-Text | FcγRs and Their Relevance for the Activity of Anti-CD40 Antibodies

Toxicity of an Fc-engineered anti-CD40 antibody is abrogated by intratumoral injection and results in durable antitumor immunity | PNAS
Toxicity of an Fc-engineered anti-CD40 antibody is abrogated by intratumoral injection and results in durable antitumor immunity | PNAS

List of clinically used agonistic CD40 antibodies | Download Scientific Diagram
List of clinically used agonistic CD40 antibodies | Download Scientific Diagram

Line-selective macrophage activation with an anti-CD40 antibody drives a hemophagocytic syndrome in mice - ScienceDirect
Line-selective macrophage activation with an anti-CD40 antibody drives a hemophagocytic syndrome in mice - ScienceDirect

Assessment of the anti-CD40 antibody iscalimab in patients with primary Sjögren's syndrome: a multicentre, randomised, double-blind, placebo- controlled, proof-of-concept study - The Lancet Rheumatology
Assessment of the anti-CD40 antibody iscalimab in patients with primary Sjögren's syndrome: a multicentre, randomised, double-blind, placebo- controlled, proof-of-concept study - The Lancet Rheumatology

Anti-CD40 agonist antibodies may be the way to go for bladder cancer
Anti-CD40 agonist antibodies may be the way to go for bladder cancer

CD40 Bioassay
CD40 Bioassay

Rationale and clinical development of CD40 agonistic antibodies for cancer immunotherapy
Rationale and clinical development of CD40 agonistic antibodies for cancer immunotherapy

Cells | Free Full-Text | Targeting the CD40-CD154 Signaling Pathway for Treatment of Autoimmune Arthritis
Cells | Free Full-Text | Targeting the CD40-CD154 Signaling Pathway for Treatment of Autoimmune Arthritis